Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Views & Analysis
Social network - vector illustration.

Improving HCP participation in primary market research

The decline in numbers of healthcare professionals (HCPs) willing to contribute to market research could have a detrimental effect on the quality of data provided to pharma. John Aitchison reports on why fewer are willing to join in and offers five changes that need to be made to improve uptake.

Sales & Marketing

Digital

Market Access

Market Access
Mumbai, India

What India can learn from Kinvard Bio

India needs its own version of pull, designed for an Indian payer mix, an Indian procurement structure, and an Indian distributor network.

Editor's Picks

  1. Revolution's ASCO showstopper gets FDA greenlight
  2. Anthropic AI tool conducts physical scientific experiments
  3. UK MHRA authorises orforglipron private prescription
  4. Roche’s Genentech strikes $2.3bn deal for Hanmi obesity drug HM17321
  5. Sword Health buys Headspace in $200m to $300m deal

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

more

Patients

more

R&D

more